ArticleMetabolic engineering2019
Engineering Saccharomyces cerevisiae for production of simvastatin.
Article in Metabolic engineering, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 52 citations in OpenAlex.
- Black yeasts are efficient heterologous hosts for the production of a wide range of fungal polyketides.Nature chemical biology · 2026Article
- Biosynthesis of the α-D-mannosidase inhibitor (-)-Swainsonine.Nature chemical biology · 2026Article
- Cysteine S-conjugate sulfoxide β-lyase activity for human ACCS.The FEBS journal · 2025Article
- Synthetic Biology in Natural Product Biosynthesis.Chemical reviews · 2025Review
- Discovery of Cortinarius O-methyltransferases for the heterologous production of dermolutein and physcion.Biotechnology for biofuels and bioproducts · 2025Article
- Pathway reconstruction and metabolic engineering for the de novo and enhancing production of monacolin J in Pichia pastoris.Bioprocess and biosystems engineering · 2024Article
- Metabolic Engineering and Synthetic Biology Approaches for the Heterologous Production of Aromatic Polyketides.International journal of molecular sciences · 2023Review
- High-Titer Production of the Fungal Anhydrotetracycline, TAN-1612, in Engineered Yeasts.ACS synthetic biology · 2022Article
- Heterologous Synthesis of Monacolin J by Reconstructing Its Biosynthetic Gene Cluster inJournal of fungi (Basel, Switzerland) · 2022Article
- Engineered Production of Strictosidine and Analogues in Yeast.ACS synthetic biology · 2022Article
- Cloning and Functional Characterization of the Polyketide Synthases Based on Genome Mining ofFrontiers in microbiology · 2022Article
- Saccharomyces cerevisiae as host for the recombinant production of polyketides and nonribosomal peptides.Microbial cell factories · 2021Review
- Heterologous production of cyanobacterial compounds.Journal of industrial microbiology & biotechnology · 2021Review
- Multiplex Genome Editing in Yeast by CRISPR/Cas9 - A Potent and Agile Tool to Reconstruct Complex Metabolic Pathways.Frontiers in plant science · 2021Review
- Synthetic biology enabling access to designer polyketides.Current opinion in chemical biology · 2020Review
- Green Synthesis of the Flavor Esters with a MarineIndian journal of microbiology · 2020Article
- Genetic platforms for heterologous expression of microbial natural products.Natural product reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Simvastatin is a semisynthetic cholesterol-lowering medication and one of the top-selling statins in the world. Currently, industrial production of simvastatin acid (SVA) is a multistep process starting from the natural product lovastatin. For this reason, there is significant interest in direct production of simvastatin from a microbial host. In this study, six heterologous biosynthetic genes were introduced into Saccharomyces cerevisiae and the acyl-donor dimethylbutyryl-S-methyl mercaptopropionate (DMB-SMMP) was added, resulting in initial production of 0.5 mg/L SVA. Switching the yeast strain from JHY686 to BJ5464-NpgA increased total polyketide production to over 60 mg/L and conversion from dihydromonacolin L acid to monacolin J acid (MJA) was increased from 60% to 90% by tuning the copy number of the P450 lovA. Increasing the media pH to 8.7 led to a further 10-fold increase in SVA production. Optimized chemical lysis of the cell walls in situ after maximum MJA production led to 55 mg/L SVA titer, representing nearly complete conversion from MJA and a 110-fold increase in titer from the initial SVA production strain. The yeast strains developed in this work can be used as an alternative production method for SVA, and the strategies employed can be broadly applied for heterologous production of other fungal polyketides and semisynthetic compounds in yeast.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.